Yes, antiplatelet therapy must be started immediately for acute to subacute frontal lobe infarcts, regardless of intermittent headache.
A patient with CT-confirmed acute to subacute infarcts in the frontal lobes requires immediate antiplatelet therapy—this is a Grade 1A recommendation and takes priority over headache management. The presence of headache does not contraindicate antiplatelet therapy and should not delay treatment 1, 2.
Immediate Management Algorithm
Step 1: Confirm Timing and Stroke Severity
- If symptoms began within 48 hours: Start aspirin 160-325 mg immediately as a loading dose after confirming no intracranial hemorrhage on CT 1, 3
- Perform dysphagia screening before oral administration 2
- If unable to swallow: Give aspirin 80 mg via enteral tube or 325 mg rectal suppository 2
Step 2: Determine if Dual Antiplatelet Therapy is Indicated
Start dual antiplatelet therapy (aspirin + clopidogrel) if:
- NIHSS score 0-3 (minor stroke) AND
- Symptoms began within 24 hours (ideally within 12 hours) 2
Dosing for dual therapy:
- Clopidogrel loading dose: 300-600 mg
- Aspirin loading dose: 160 mg
- Continue both for 21-30 days only, then switch to monotherapy 2, 3
Do NOT use dual therapy if:
- NIHSS >3 (moderate-severe stroke)
- Symptoms began >24 hours ago
- Patient received IV thrombolysis (delay antiplatelet therapy 24 hours post-tPA) 2, 4
Step 3: Long-term Antiplatelet Therapy
After the initial period, continue indefinitely with one of:
- Aspirin 75-100 mg daily, OR
- Clopidogrel 75 mg daily (preferred over aspirin alone) 1
Critical Considerations for This Case
The headache is clinically irrelevant to antiplatelet decision-making. Intermittent headache does not increase bleeding risk sufficiently to withhold antiplatelet therapy in acute ischemic stroke 5. The proven mortality and morbidity reduction from antiplatelet therapy (13 fewer deaths or dependencies per 1000 patients treated) far outweighs theoretical concerns 6.
Common pitfall: Delaying antiplatelet therapy due to concern about hemorrhagic transformation. The evidence is clear—early aspirin (within 48 hours) reduces death or dependency with only a minor increase in bleeding complications 1, 6. The two landmark trials (IST and CAST) involving over 40,000 patients demonstrated net benefit when aspirin was started within 48 hours 6.
Timing is critical: Every hour of delay reduces the benefit. The recommendation specifies starting "as soon as possible" after brain imaging excludes hemorrhage 2, 3. For dual antiplatelet therapy in minor strokes, the window is even narrower—within 24 hours, ideally within 12 hours 2.
What NOT to Do
- Do not use anticoagulation for acute noncardioembolic stroke—it increases hemorrhagic complications without reducing early recurrent stroke 4
- Do not withhold aspirin to perform additional workup for the headache
- Do not use dual antiplatelet therapy beyond 30 days—bleeding risk increases while benefit plateaus 2
- Do not substitute other agents without evidence (e.g., dipyridamole, cilostazol) in the acute phase—aspirin has the strongest evidence 1, 6
Addressing the Headache
The headache requires evaluation but should not delay stroke treatment. After initiating antiplatelet therapy, investigate headache etiology if it persists or worsens, but the stroke treatment protocol takes absolute priority. The presence of infarcts on CT confirms this is a cerebrovascular event requiring immediate secondary prevention 3.